icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
FINAL RESULTS: Randomized, Double-blind, Placebo-controlled Safety, Anti-viral, Proof of Concept Study of Miravirsen, an Oligonucleotide Targeting miR-122, in Treatment-Na´ve Patients with Genotype 1 Chronic HCV Infection
 
 
  Reported by Jules Levin
EASL 2012
 
H. W. Reesink1; H. L. A. Janssen2; S. Zeuzem3; E. Lawitz4; M. Rodriguez-Torres5; K. Patel6; A. Chen7; C. Davis7; B. King7; A. A. Levin7; M. R. Hodges7
 
1. Academic Medical Center, Amsterdam, The Netherlands
2. Erasmus MC University Hospital, Rotterdam, The Netherlands
3. J.W. Goethe University Hospital, Frankfurt, Germany
4. Alamo Medical Research, San Antonio, TX, United States
5. Fundacion de Investigacion de Diego, San Juan, Puerto Rico
6. Duke University, Durham, NC
7. Santaris Pharma A/S, San Diego, CA, United States

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif

EASL13.gif

EASL14.gif